In vivo immune cell engineering directly reprograms endogenous immune cells, bypassing individualized ex vivo manufacturing and opening a path toward more accessible and scalable cell therapies. This review summarizes cell-specific engineering strategies, compares viral and non-viral delivery platforms, highlights emerging applications in cancer, autoimmune and degenerative diseases, and discusses the key challenges that must be overcome for clinical translation.

Researchers have developed a recombinant, nanobody-based antivenom that offers broad protection against venom from geographically diverse cobra and king cobra species in India

In 2024, malignant tumors caused more than 21,300 deaths in Austria, 4.7% more than in 2014. Faced with a similarly pressing global challenge, scientists are striving to better understand what drives cancer cells to grow, spread, and invade healthy tissue. In Science Advances, a team at the Institute of Science and Technology Austria (ISTA) now offers new clues: Using a simplified model, the researchers show how a chaotic environment around tumor cells can promote their invasive behavior. This theoretical concept will need to be examined further in real tumor tissue.

ATLANTA — A multi-institutional research team led by Georgia State University Regents’ Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches. Results of this research, recently published in the journal Science Advances, report a precision MRI method that can identify tumors and metastases as small as 1 millimeter.

A groundbreaking new review article, titled “Recent advances in precise synthesis, functional modification and multidisease theranostic applications of layered double hydroxide nanomaterials,” offers a definitive roadmap for the next generation of smart nanomedicine. Published in Frontiers of Materials Science, this comprehensive study synthesizes decades of research to highlight the transformative potential of layered double hydroxides (LDHs) in treating complex diseases ranging from cancer to neurodegenerative disorders.

BUFFALO, NY – September 9, 2026 – A new review was published in Volume 17 of Oncotarget on September 8, 2026, titled “Re-expression of MHC-I to treat CNS cancers.”